Company / Net Income
CytomX Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$17.4M
FY2025
5-year range
-$115.9M / $31.9M
FY2021-FY2025
Trend
-154.5%
vs FY2024
Sector context
#69 of 216
Health Care
What the data says
At -$17M, CytomX Therapeutics, Inc.'s net income ranks #69 of 216 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$116M in FY2021 to $32M in FY2024.
Based on SEC 10-K filings.
-$17M in FY2025.
Declined from -$569,000 to -$17M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#69 of 216 in Health CareTop 32% of 216This company -$17.4M Sector average $454.3M
▼
-103.8% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 154.5% year-over-year.
- Ranks #69 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$17.4M | -154.5% |
| FY2024 | $31.9M | +5700.9% |
| FY2023 | -$569.0K | +99.4% |
| FY2022 | -$99.3M | +14.3% |
| FY2021 | -$115.9M | -252.3% |
| FY2020 | -$32.9M | +67.8% |
| FY2019 | -$102.2M | -20.8% |
| FY2018 | -$84.6M | -96.3% |
| FY2017 | -$43.1M | +26.8% |
| FY2016 | -$58.9M | -289.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026